“Efficacy and Tolerability of Valganciclovir 6 Months vs 6 Weeks in Symptomatic Cytomegalovirus Infection in Infants: An Open Level Randomized Controlled Trial” (2022) European Journal of Clinical Medicine, 3(1), pp. 18–25. doi:10.24018/clinicmed.2022.3.1.122.